Sarah E Nelson1, Zsuzsanna Ament1, Zoe Wolcott1, Robert E Gerszten1, W Taylor Kimberly2. 1. From the Departments of Neurology and Anesthesiology/Critical Care Medicine (S.E.N.), Johns Hopkins Hospital, Baltimore, MD; Center for Genomic Medicine (Z.A., Z.W., W.T.K.) and Division of Neurocritical Care and Emergency Neurology, Department of Neurology (Z.A., Z.W., W.T.K.), Massachusetts General Hospital, Harvard Medical School; and Division of Cardiovascular Medicine (R.E.G.), Beth Israel Deaconess Hospital, Boston, MA. 2. From the Departments of Neurology and Anesthesiology/Critical Care Medicine (S.E.N.), Johns Hopkins Hospital, Baltimore, MD; Center for Genomic Medicine (Z.A., Z.W., W.T.K.) and Division of Neurocritical Care and Emergency Neurology, Department of Neurology (Z.A., Z.W., W.T.K.), Massachusetts General Hospital, Harvard Medical School; and Division of Cardiovascular Medicine (R.E.G.), Beth Israel Deaconess Hospital, Boston, MA. wtkimberly@mgh.harvard.edu.
Abstract
OBJECTIVE: To determine whether altered metabolic profiles represent a link between atrial dysfunction and cardioembolic (CE) stroke, and thus whether underlying dysfunctional atrial substrate may contribute to thromboembolism risk in CE stroke. METHODS: A total of 144 metabolites were measured using liquid chromatography-tandem mass spectrometry in plasma samples collected within 9 hours of stroke onset in 367 acute stroke patients. Stroke subtype was assigned using the Causative Classification of Stroke System, and CE stroke (n = 181) was compared to non-CE stroke (n = 186). Markers of left atrial dysfunction included abnormal atrial function (P-wave terminal force in lead V1, PTFV1 >4,000 μV·ms), left atrial enlargement on echocardiography, and frank atrial fibrillation on ECG. Stroke recurrence risk was assessed using CHADS2 and CHA2DS2-VASc scores. Associations between metabolites and CE stroke, atrial dysfunction, and stroke recurrence risk were evaluated using logistic regression models. RESULTS: Three tricarboxylic acid metabolites-succinate (odds ratio [OR] 1.71, 95% confidence interval [CI] 1.36-2.15, p = 1.37 × 10-6), α-ketoglutarate (OR 1.62, 95% CI 1.29-2.04, p = 1.62 × 10-5), and malate (OR 1.58, 95% CI 1.26-1.97, p = 2.57 × 10-5)-were associated with CE stroke. Succinate (OR 1.36, 95% CI 1.31-1.98, p = 1.22 × 10-6), α-ketoglutarate (OR 2.14, 95% CI 1.60-2.87, p = 2.08 × 10-8), and malate (OR 2.02, 95% CI 1.53-2.66, p = 1.60 × 10-7) were among metabolites also associated with subclinical atrial dysfunction. Of these, succinate was also associated with left atrial enlargement (OR 1.54, 95% CI 1.23-1.94, p = 1.06 × 10-4) and stroke recurrence based on dichotomized CHADS2 (OR 2.63, 95% CI 1.68-4.13, p = 3.00 × 10-6) and CHA2DS2-VASc (OR 2.43, 95% CI 1.60-3.68, p = 4.25 × 10-6) scores. CONCLUSIONS: Metabolite profiling identified changes in succinate associated with CE stroke, atrial dysfunction, and stroke recurrence, revealing a putative underlying link between CE stroke and energy metabolism.
OBJECTIVE: To determine whether altered metabolic profiles represent a link between atrial dysfunction and cardioembolic (CE) stroke, and thus whether underlying dysfunctional atrial substrate may contribute to thromboembolism risk in CE stroke. METHODS: A total of 144 metabolites were measured using liquid chromatography-tandem mass spectrometry in plasma samples collected within 9 hours of stroke onset in 367 acute stroke patients. Stroke subtype was assigned using the Causative Classification of Stroke System, and CE stroke (n = 181) was compared to non-CE stroke (n = 186). Markers of left atrial dysfunction included abnormal atrial function (P-wave terminal force in lead V1, PTFV1 >4,000 μV·ms), left atrial enlargement on echocardiography, and frank atrial fibrillation on ECG. Stroke recurrence risk was assessed using CHADS2 and CHA2DS2-VASc scores. Associations between metabolites and CE stroke, atrial dysfunction, and stroke recurrence risk were evaluated using logistic regression models. RESULTS: Three tricarboxylic acid metabolites-succinate (odds ratio [OR] 1.71, 95% confidence interval [CI] 1.36-2.15, p = 1.37 × 10-6), α-ketoglutarate (OR 1.62, 95% CI 1.29-2.04, p = 1.62 × 10-5), and malate (OR 1.58, 95% CI 1.26-1.97, p = 2.57 × 10-5)-were associated with CE stroke. Succinate (OR 1.36, 95% CI 1.31-1.98, p = 1.22 × 10-6), α-ketoglutarate (OR 2.14, 95% CI 1.60-2.87, p = 2.08 × 10-8), and malate (OR 2.02, 95% CI 1.53-2.66, p = 1.60 × 10-7) were among metabolites also associated with subclinical atrial dysfunction. Of these, succinate was also associated with left atrial enlargement (OR 1.54, 95% CI 1.23-1.94, p = 1.06 × 10-4) and stroke recurrence based on dichotomized CHADS2 (OR 2.63, 95% CI 1.68-4.13, p = 3.00 × 10-6) and CHA2DS2-VASc (OR 2.43, 95% CI 1.60-3.68, p = 4.25 × 10-6) scores. CONCLUSIONS: Metabolite profiling identified changes in succinate associated with CE stroke, atrial dysfunction, and stroke recurrence, revealing a putative underlying link between CE stroke and energy metabolism.
Authors: Danny Alexander; Raffaella Lombardi; Gabriela Rodriguez; Matthew M Mitchell; Ali J Marian Journal: Eur J Clin Invest Date: 2010-12-14 Impact factor: 4.686
Authors: Dina Vojinovic; Sven J van der Lee; Cornelia M van Duijn; Meike W Vernooij; Maryam Kavousi; Najaf Amin; Ayşe Demirkan; M Arfan Ikram; Aad van der Lugt; Daniel Bos Journal: Atherosclerosis Date: 2018-03-08 Impact factor: 5.162
Authors: S L Kopecky; B J Gersh; M D McGoon; J P Whisnant; D R Holmes; D M Ilstrup; R L Frye Journal: N Engl J Med Date: 1987-09-10 Impact factor: 91.245
Authors: Hannah J Irvine; Animesh Acharjee; Zoe Wolcott; Zsuzsanna Ament; H E Hinson; Bradley J Molyneaux; J Marc Simard; Kevin N Sheth; W Taylor Kimberly Journal: Cell Rep Med Date: 2022-06-13
Authors: Zsuzsanna Ament; Amit Patki; Ninad Chaudhary; Varun M Bhave; Ana-Lucia Garcia Guarniz; Yan Gao; Robert E Gerszten; Adolfo Correa; Suzanne E Judd; Mary Cushman; D Leann Long; M Ryan Irvin; W Taylor Kimberly Journal: Neurology Date: 2022-03-09 Impact factor: 11.800
Authors: Mònica Bulló; Christopher Papandreou; Jesus García-Gavilán; Miguel Ruiz-Canela; Jun Li; Marta Guasch-Ferré; Estefanía Toledo; Clary Clish; Dolores Corella; Ramon Estruch; Emilio Ros; Montserrat Fitó; Chih-Hao Lee; Kerry Pierce; Cristina Razquin; Fernando Arós; Lluís Serra-Majem; Liming Liang; Miguel A Martínez-González; Frank B Hu; Jordi Salas-Salvadó Journal: Metabolism Date: 2021-10-20 Impact factor: 13.934
Authors: Zsuzsanna Ament; Matthew B Bevers; Zoe Wolcott; W Taylor Kimberly; Animesh Acharjee Journal: Transl Stroke Res Date: 2020-10-17 Impact factor: 6.829
Authors: Brian L Edlow; Yelena G Bodien; Timothy Baxter; Heather G Belanger; Ryan J Cali; Katryna B Deary; Bruce Fischl; Andrea S Foulkes; Natalie Gilmore; Douglas N Greve; Jacob M Hooker; Susie Y Huang; Jessica N Kelemen; W Taylor Kimberly; Chiara Maffei; Maryam Masood; Daniel P Perl; Jonathan R Polimeni; Bruce R Rosen; Samantha L Tromly; Chieh-En J Tseng; Eveline F Yao; Nicole R Zürcher; Christine L Mac Donald; Kristen Dams-O'Connor Journal: J Neurotrauma Date: 2022-06-29 Impact factor: 4.869